Modulation of Toll-like Receptor Signalling as a New Therapeutic Principle
1Department of Pneumology, University Hospital of Bern, 3010 Bern, Switzerland
2Department of Dermatology and Allergy, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany
3Department of Biochemistry, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK
4School of Biochemistry and Immunology, Trinity College Dublin, Ireland
5Opsona Therapeutics Ltd., The Trinity Centre for Health Sciences, Institute of Molecular Medicine, St. James's Hospital, Dublin, Ireland
6Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, 81675 Munich, Germany
Modulation of Toll-like Receptor Signalling as a New Therapeutic Principle
Description
The past 10 years in immunology were characterized by breakthrough progress in the field of innate immunity, especially by the definition of the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily. Toll-like receptors are pattern recognition receptors that play a predominant role for innate immunity and inflammation. After much insights into the basic signalling events, the next step will be to unravel the therapeutic potential of the modulation of different TLR/IL1R-pathways. These pathways are involved in many different pathologies, and the therapeutic interference could have a substantial clinical benefit in a variety of diseases, ranging from allergy, over atherosclerosis, to cancer.
We invite authors to present original research articles as well as review articles that will stimulate the continuing efforts in defining the role of innate immunity signalling pathways in clinical applications. We are particularly interested in manuscripts that report the clinical applications of approved or investigational TLR-modulating therapy in various fields of medicine (cardiovascular, oncology, dermatology, pneumology, etc.) with emphasis on efficacy, toxicity, response assessment, prognostic factors, and predictive markers. Reviews that summarize the results of basic research on Toll-like receptors and innate immunity receptors, or those receptors as targets in clinical trials and their future implications on treatment practice, are particularly welcome. Potential topics include but are not limited to:
- Clinical implications of innate immune signalling
- Therapeutical exploitation of signalling
- Clinical trials on innate immune signalling
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/mi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: